Aug. 10 at 11:11 AM
H.C. Wainwright⬆️
$IMMX's PT to
$25, reiterated Buy and said -- For 2Q26, Immix reported a net loss of
$0.18 per share vs. our prior estimate of a net loss of
$0.15 per share.
$PRTA $JNJ - GMAB AZN ABBV REGN
H.C. Wainwright added—R&D and SG&A expenses were
$5.3M and
$7.1M respectively, vs. our prior estimates of
$6.2M and
$4.9M. We now project a full-year 2026 net loss of
$0.72 per share vs. our prior net loss estimate of
$0.62 per share.
Immix ended 2Q26 with ~
$234.2M in cash—providing an operational runway extending into mid-2027, in our view.
After advancing our discounted cash flow (DCF)-based valuation and taking into account ex-U.S. sales from NXC-201, we reiterate our Buy rating and raise our 12-month price target to
$25 from the prior
$20 per share.
